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OBJECTIVE — Thepurposeofthisstudywastoassesstheefﬁcacyofaninsulinprimingdose
with a continuous insulin infusion versus two continuous infusions without a priming dose.
RESEARCH DESIGN AND METHODS — This prospective randomized protocol used
threeinsulintherapymethods:1)loadgroupusingaprimingdoseof0.07unitsofregularinsulin
per kg body weight followed by a dose of 0.07 unit   kg
1   h
1 i.v. in 12 patients with diabetic
ketoacidosis (DKA); 2) no load group using an infusion of regular insulin of 0.07 unit   kg body
weight
1 h
1withoutaloadingdosein12patientswithDKA,and3)twicenoloadgroupusing
aninfusionofregularinsulinof0.14 kg
1 h
1withoutaloadingdosein13patientswithDKA.
Outcome was based on the effects of insulin therapy on biochemical and hormonal changes
during treatment and recovery of DKA.
RESULTS — The load group reached a peak in free insulin value (460 U/ml) within 5 min
and plateaued at 88 U/ml in 60 min. The twice no load group reached a peak (200 U/ml) at
45 min. The no load group reached a peak (60 U/ml) in 60–120 min. Five patients in the no
load group required supplemental insulin doses to decrease initial glucose levels by 10%; pa-
tients in the twice no load and load groups did not. Except for these differences, times to reach
glucose 250 mg/dl, pH 7.3, and HCO3
 15 mEq/l did not differ signiﬁcantly among the
three groups.
CONCLUSIONS — A priming dose in low-dose insulin therapy in patients with DKA is
unnecessary if an adequate dose of regular insulin of 0.14 unit   kg body weight
1   h
1 (about
10 units/h in a 70-kg patient) is given.
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A
lthough positive therapeutic re-
sponsestolow-doseinsulintherapy
have been established in adult pa-
tients with diabetic ketoacidosis (DKA)
(1–8), none of these studies and guide-
lines for the treatment of DKA, including
theAmericanDiabetesAssociation(ADA)
Consensus and Position Statements, has
ever assessed or addressed the use of a
continuous insulin infusion without a
loading dose of insulin (9). In the current
study, we used a dose of 0.14 unit   kg
1  
h
1 without a loading dose instead of the
recommended0.1unit kg
1 h
1witha
loading dose. This insulin regimen was
chosen because one study in a pediatric
population used a dosing regimen of 0.1
unit   kg
1   h
1 without a loading dose
thatresultedinatotalplasmainsulinlevel
of 50–60 U/ml (10). This level proved
to be too low for optimal suppression of
hepatic glucose output and optimal glu-
coseuptake(11).Inaddition,bolusdoses
of insulin may result in hypokalemia as
well as other undesirable effects (12), es-
pecially when used in a routine hospital
setting.
Theefﬁcacyoflow-doseinsulinwith-
out a priming dose has not been estab-
lished in a prospective randomized study
(13). Thus, the following questions have
remained unanswered in the treatment of
DKA: 1) Is an insulin bolus needed before
a continuous insulin infusion? 2) What is
theoptimalinsulininfusionrateifabolus
dose is not used? and 3) What is the dose
response of continuous insulin infusion
used alone in regard to decremental
changes in glucose, metabolic parame-
ters, cortisol, and free fatty acids (FFAs)?
Therefore, we evaluated responses to
three low-dose insulin regimens in 37
consecutive patients with DKA in a pro-
spective randomized fashion to address
these issues. Changes in plasma free insu-
lin, serum potassium levels, and outcome
recovery measures were assessed using a
higher infusion dose (0.14 unit   kg
1  
h
1withoutabolusdose)comparedwith
a lower infusion dose (0.07 unit   kg
1  
h
1) with and without a loading dose
(0.07 unit/kg) of insulin.
RESEARCH DESIGN AND
METHODS— Our criteria for the di-
agnosis of DKA included plasma glucose
250 mg/dl, HCO3
 15 mEq/l, pH
7.3, and moderate ketones in the urine
or blood by the nitroprusside method. A
total of 37 patients were prospectively
randomly assigned to three groups as fol-
lows: 1) the load group consisted of 12
patients who received a loading dose of
insulin at 0.07 unit/kg body weight fol-
lowed by an infusion of 0.07 unit   kg
bodyweight
1 h
1;2)thenoloadgroup
consisted of 12 patients who received
only an intravenous infusion of insulin at
a dose of 0.07 unit   kg body weight
1  
h
1 without a loading dose; or 3) the
twice no load group consisted of 13 pa-
tients who received an infusion of insulin
at a dose of 0.14 unit   kg body weight
1  
h
1 without a bolus dose. Responses to
therapywerebasedonthetimetoachieve
a glucose level of 250 mg/dl, bicarbon-
ateof15mEq/l,andpH7.3.Allother
modes of therapy (hydrating solution,
KCl, and HCO3
) were similar in the
three groups and followed the recom-
mendations of the ﬁrst ADA position
statement (6). All patients were seen in
the emergency department of the Re-
gional Medical Center at Memphis. Upon
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ical examination was performed. Urine
ketones (by nitroprusside) plus glucose
by ﬁngerstick and blood gas measure-
mentswereobtainedimmediately.Oncea
suspected diagnosis of DKA was made,
the initial laboratory blood samples were
obtained for basal metabolic parameters
and complete blood count with differen-
tial; urinalysis was performed for blood
and urine ketones by both the nitroprus-
side and enzymatic methods. Patients
then received 1 liter of 0.9% NaCl per
hour until laboratory results were avail-
able. After laboratory conﬁrmation, the
intravenous ﬂuids were adjusted, de-
pending on the glucose and corrected se-
rum sodium value, to 1⁄2 N saline or
dextrose with1No r1⁄2 N saline. With
conﬁrmation of the diagnosis of DKA and
an acceptable potassium level (3.3
mEq/l),thepatientswerethentransferred
to the Clinical Research Center (CRC) of
theUniversityofTennesseeBowldHospi-
tal after the research study was described
to the patients or their next of kin and the
consentform,whichwasapprovedbythe
University of Tennessee Health Science
Center of Memphis Institutional Review
Board, was signed. On arrival at the CRC,
the treatment and care of patients was
managed by the DKA team, including the
medicalhousestaffonrotationfortheser-
vice, following an established protocol
with consultation of the staff endocrinol-
ogist. Hourly blood glucose measure-
ments and blood samples for free insulin
wereobtainedat0,5,15,30,45,60,120,
240,and480min.Bloodformeasurement
of other hormones and ketone bodies,
blood gases, and metabolic proﬁle; urinaly-
sis for ketones; and other parameters were
obtained.Randomassignmentofpatientsto
different insulin regimens was done after
Table 1—Demographics and clinical data of 37 patients with DKA with three intravenous
insulin protocols
Load No load Twice no load
n 12 12 13
Age (years) 28.6  2.3 (19–44) 37.3  4.2 (20–66) 31.8  2.8 (17–50)
Sex
Female 4 9 6
Male 8 3 7
Race
Caucasian 4 0 4
African American 8 12 9
BMI (kg/m
2) 22.1  1.6 24.6  2.6 22.1  1.3
Duration of diabetes (years) 8.5  1.7 5.6  2.0 8.0  2.5
Treatment
None 2 5 2
Diet 2
Insulin 10 7 9
Precipitating factor
Lack of insulin 6 6 5
Infection 3 4 5
Other 3 2 3
Blood pressure
Systolic (mmHg) 125  8 127  8 128  5
Diastolic (mmHg) 66  38 1  48 2  4
Pulse (beats/min) 109  3 108  5 113  6
Respiratory rate (per min) 27  1.0 24  1.0 29  1.0
Mental status
Alert 9 5 5
Drowsy 3 5 7
Stupor 1 1
Comatose 1
Data are means  SEM, means  SEM (range), or n.
Table 2—Biochemical and hormonal data at baseline and recovery of patients with DKA receiving three insulin protocols
Load No load Twice no load
Baseline Recovery Baseline Recovery Baseline Recovery
Sodium (mEq/l) 131  2 137  1.1 137  3 136  3.2 131  1 136  1.8
Potassium (mEq/l) 5.4  0.3 4.0  0.14 4.8  0.2 3.8  0.14 5.5  0.3 3.8  0.09
Bicarbonate (mEq/l) 6.7  0.7 17.8  1.0 5.9  0.8 16.2  0.43 4.9  0.5 16.0  0.35
Glucose (mg/dl) 578  64 162  12 459  38 133  15 522  47 110  9
Blood urea nitrogen (mg/dl) 29  6 16.3  3.8 21  4 16.3  4.2 22  2 17.2  2.9
Anion gap (mEq/l) 27  1 11.3  1.8 24  2 7.8  1.7 27  2 10.3  1.7
pH 7.12  0.03 7.3  0.01 7.15  00.03 7.31  0.01 7.07  0.02 7.32  0.01
-Hydroxybutyrate (mmol/l) 10.5  1.1 2.4  0.5 8.8  0.9 2.7  0.6 10.5  1.2 2.5  0.4
Acetoacetate (mmol/l) 2.5  0.3 1.06  0.19 2.6  0.3 1.20  0.34 2.4  0.4 0.90  0.20
Total ketones (mmol/l) 13.0  1.1 3.5  0.7 11.4  1.0 3.9  0.9 13.2  1.5 3.5  0.5
Pyruvate (mg/dl) 0.6  0.1 0.34  0.06 0.7  0.3 0.35  0.08 0.9  0.2 0.65  0.09*
Lactate (mg/dl) 18.3  3.8 7.9  1.3 13.7  1.6 8.3  0.8 19.5  2.3 10.7  2.1
Free fatty acid (mmol/l) 1.92  0.18 0.74  0.09 1.83  0.23 1.00  0.17 2.14  0.10 1.92  0.10
Free insulin (U/ml) 4.17  1.82 ND 6.66  1.76 ND 3.69  1.69 ND
C-peptide (pmol/ml) 0.08  0.07 ND 0.14  0.1 ND 0.11  0.05 ND
Cortisol (g/dl) 72  12 27.1  4.7 54  11 26.9  9.6 83  12 33.2  5.8
Data are means  SEM. *P  0.05, compared with the other groups. ND, not done.
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wasnotbasedonsexorethnicity.Because
a priming dose of insulin adds an addi-
tionalriskofhypokalemia,potassiumlev-
els were assessed and corrected on an
hourlybasisfortheﬁrstfewhoursofther-
apy until glucose reached the predeter-
mined goal of 250 mg/dl (i.e., 4h )
and every 2 h thereafter.
Laboratory procedures
Laboratory studies included complete
blood cell count, blood gas measure-
ments,androutinebloodchemistryvalues
measured by standard assays in the clinical
chemistry laboratory. In addition, plasma
freeinsulin,C-peptide,-hydroxybutyrate,
acetoacetate, pyruvate, lactate, cortisol, and
FFAs were assayed. Glucose was measured
by a glucose oxidase method using a Beck-
man glucose analyzer. Plasma free insulin
and C-peptide were measured after poly-
ethylene glycol precipitation by a double-
antibody radioimmunoassay method (14).
Cortisol, FFAs, and ketone bodies were de-
termined by previously described methods
(2,15).
Data analysis
Overall mean comparisons for means and
slopes for the three groups (load, no load,
and twice no load) were made with one-
way ANOVA using the Clinfo and SAS
(SAS Institute, Cary, NC) software pack-
ages. These were followed by pairwise
comparisons of averages and regression
estimates of the slopes by observing the
overlap/nonoverlap of the 95% conﬁ-
dencelimitsforalloftheestimates(means
and slopes). If any 95% conﬁdence limits
foranestimateoverlapped,thennostatis-
tical signiﬁcance was declared at P 
0.05. If there was no overlap due to vari-
ability, then statistical signiﬁcance was
declared at P  0.05. This signiﬁcance
and nonsigniﬁcance is denoted by super-
script letters (as in Table 4). Thus, groups
having superscripts in common are not
signiﬁcant at P  0.05, whereas those
having no superscripts in common are
signiﬁcant at P  0.05.
RESULTS
Demographic and initial clinical
data
Table 1 shows the baseline characteristics
of patients in the three treatment groups,
withthefollowingﬁndings:1)noneofthe
patientswereobese,2)themajorityofthe
patientswereAfricanAmericansandwere
receiving insulin therapy, 3) omission of
insulin (47%) and infection (33%) were
the major precipitating factors for DKA,
and 4) within the load group there were
twice as many men as women, within the
no load group there were three times as
many women as men, and within the
twice no load group men and women
were equally distributed. However, in all
of these groups, the majority of subjects
were African American.
Biochemical data on admission and
after recovery
Table 2 shows biochemical data on ad-
mission and at complete recovery from
Figure 1—Kinetics of three doses of low-dose insulin in patients with DKA.
Table 3—Outcome data for three doses of intravenous insulin in DKA
Load No load Twice no load
n 12 12 13
Hours to glucose control (250 mg/dl) 4.33  0.66 4.67  0.83 3.69  0.46
Hours to bicarbonate control (15 mEq/l) 10.3  1.9 13.8  2.8 9.62  1.1
Hours to pH control (7.3) 8.33  1.88 8.08  1.74 8.46  1.11
Hours to recovery 11.1  1.7 13.8  2.8 10.2  1.1
Insulin dose to recovery (units) 48.2  9.5 81.3  18.5 80.0  9.5
Intravenous ﬂuid given (ml)
First 8 h 3,740  410 4,210  440 3,570  250
First 24 h 7,170  600 7,950  490 7,510  300
Complications 0 0 0
Deaths 0 0 0
Days in hospital 5.9  0.7 4.7  0.6 6.9  0.7
Data are means  SEM.
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were no statistically signiﬁcant differ-
ences among any of the parameters in the
groups on admission, cortisol values are
lower in the no load group than in the
other two groups. It is of interest that all
the subjects in this group are African
Americans, the majority are women, and
the free insulin level in this group is also
about twice that of the other two groups.
However, this counter-regulatory hor-
mone, similar to that in previous reports
(5,16,17), is still twofold higher than the
baseline value. All measured parameters
reached their near-normal values at re-
covery, with total ketone bodies reaching
3.5 mmol/l. Of interest was the FFA
level, which at recovery was about twice
the normal value but consistent with ele-
vated levels of FFA in diabetic patients
withoutDKA(16).Themeananiongapat
recovery was 12.
Figure 1 demonstrates the kinetics of
intravenous insulin after infusion in the
three arms. This ﬁgure shows that infu-
sion of insulin of 0.07 (no load) or 0.14
unit   kg
1   h
1 (twice no load) without
aninitialbolusresultedinpeaksof66and
202 U/ml, respectively, whereas the use
of an intravenous bolus of 0.07 unit/kg
followed by a 0.07 unit   kg
1   h
1 infu-
sion resulted in peak insulin of 460
U/ml at 5 min, which reached a plateau
levelof86U/mlin30min.Itisalsoof
interest that plateau levels of insulin for
both the load and no load groups are not
signiﬁcantlydifferentfrom60to120min.
However, the twice no load group (0.14
unit   kg
1   h
1, which is 10 units/h of
insulin in a 70-kg patient) maintained
higher levels of insulin during 30–120
min of infusion than those of the load or
no load group.
Effect of various doses of insulin on
recovery parameters
Table 3 demonstrates the outcome recov-
ery data for DKA, depicting the time that
predetermined values were reached for
glucose, HCO3
, and pH. The results
suggested no signiﬁcant differences in
these values for the three doses of insulin,
but 5 of 12 patients in the no load group
required additional insulin for control of
their blood glucose. The length of hospi-
talization was not signiﬁcantly different
amongthegroups,therewerenocomplica-
tions in any of the groups, and no deaths
occurred in this cohort. No hypokalemia
was noted in any treatment group. The po-
tassiumnadirswere4.3,4.2,and3.7mEq/l
in the load, no load, and twice no load
groups, respectively (Fig. 2).
Table 4 shows estimates of the slopes
for glucose, venous pH, ketones, FFAs, bi-
carbonate, and cortisol during the ﬁrst 8 h
of therapy in the three insulin therapy
groups. The response of serum bicarbonate
and cortisol showed no differences among
the treatment groups. However, the slopes
for glucose, venous pH, ketones, and FFAs
varied among treatment groups.
CONCLUSIONS — Although nu-
merous studies have effectively used low-
dose insulin in the treatment of DKA
(3,9,18), there are no data from a pro-
Figure 2—Changes in hourly serum potassium with three low-dose insulin regimens in the
treatment of DKA.
Table 4—Slope estimates for clinical and hormonal responses to therapy over the ﬁrst 8 h
Parameter
Load group No load group Twice no load group
Initial value* Estimate of slope† Initial value* Estimate of slope† Initial value* Estimate of slope†
Glucose (mg/dl) 578.1  63.7 86.49
a 459.2  38.2 52.22
b 521.9  47.0 77.67
a
Venous pH 7.1  0.03 0.029
a,b 7.13  0.03 0.025
a 7.04  0.02 0.042
b
Ketones (mmol/l) 12.98  1.14 1.92
a 10.33  1.3 0.93
b 13.17  1.47 1.23
c
FFAs (mmol/l) 1.92  0.18 0.34
a 1.83  0.23 0.21
b 2.14  0.10 0.26
a,b
Serum bicarbonate (mEq/l) 6.7  0.7 0.863
a 5.9  0.8 0.551
a 4.9  0.5 0.779
a
Cortisol (g/dl) 71.8  11.7 7.09
a 54.3  10.5 4.40
a 82.7  12.2 7.73
a
Data are means  SEM. *No signiﬁcant differences noted in initial values. †In comparisons involving load, no load, and twice no load treatment groups, those slope
estimates with the same superscript are not signiﬁcantly different at P  0.05.
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insulin bolus (0.07 U/kg) compared with
no bolus in conjunction with an infusion
of low-dose insulin (0.07 vs. 0.14 unit  
kg
1   h
1). Previous studies have dem-
onstrated that although 0.1 unit/h of in-
sulin in patients with DKA can effectively
inhibit lipolysis, this dose will only sup-
press hepatic gluconeogenesis by 50%
(11).
We had previously shown that an in-
termediate dose of insulin of 0.1 unit   kg
body weight
1   h
1 (equivalent of 7
units/h of insulin in a 70-kg patient) by
intravenous infusion was much more ef-
fectivethanadosebythesubcutaneousor
intramuscular route (4). In these studies
we used a priming dose. In addition, in a
selected case report we have used as little
as 6 units/h for a patient with modest
DKA with further maintenance of eugly-
cemia by 1–2 units/h (14). However, a
bolus dose of insulin preceded the low-
dose infusion (19). Furthermore, a prim-
ing dose has not been used for pediatric
patients with DKA (10) and has not been
recommended in the pediatric age-group
in the latest ADA consensus report (12).
Deleterious outcomes with the use of bo-
lus insulin in this group may include hy-
pokalemia as well as possible cerebral
edema (12).
In summary, our study suggests that
the use of a bolus or priming dose of in-
sulin is not necessary when an adequate
continuous insulin infusion such as 0.14
unit   kg
1   h
1 (or 10 units/h in a 70-kg
patient) is used. However, a dose of 0.07
unit   kg
1   h
1 without priming is not
adequate to obtain desired changes in
glucose without supplemental doses of
insulin.
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